Poster
Listings
All posters will be displayed at the 3rd Floor of Centre Mont Royal from 3 to 5 October 2024.
1 Omar Aimer
Addressing pharmacovigilance training gaps: insights from a Pharmacovigilance and Drug Safety online training program for Healthcare Professionals immigrating to North-America.
3 Elora Sharmin
Challenges and experiences to Establishment of a zonal pharmacovigilance centre (ZPC) in a tertiary care teaching university hospital, (BSMMU), in Bangladesh
4 Dr. Chinmaya Mahapatra
Artificial intelligence detecting data integrity in pharmacovigilance
5 Gurpreet Singh
Global Drug Development – Current Trends, Challenges and Opportunities
6 Yassir Bousliman
The Regionalization of Pharmacovigilance in Morocco: Case of the Mohammed V Military Instruction Hospital in Rabat
7 Paulo Henrique
COVID-19 vaccine administration errors or deviations reported to the Brazilian National Immunization Program: Descriptive Analysis, 2021-2023.
8 Kadda Hachem
Composition, antioxidant properties, and antibacterial preservation potential of Algerian Myrtus nivellei essential oil.
9 Saud Al-qahtani
Evaluation of LDL-C level post acute coronary syndrome “Retrospective cohort study”
10 Maria Inés Gouveia
Dug-drug Interactions as a Public Health Problem: Retrospective Study of Adverse Drug Reaction Reports from the National Portuguese Pharmacovigilance System
11 Amelia Ng
Acute Autoimmune Hepatitis Following COVID-19 mRNA Vaccination: A Population-Based Study Using Electronic Health Records in Singapore
12 Dr. Narendra Bheemraj Parihar
Adverse Drug Reaction Monitoring in Psychiatric Patients at Tertiary Care Hospital
13 Larissa Kopp
Real-world data obtained from active surveillance of adverse events following vaccination with COVID-19 vaccines using the mobile app SafeVac 2.0
14 Francoise Livio
Pitfalls in the Management of Pharmacokinetic Drug-Drug Interactions: a Focus on Anticalcineurins and Azole Antifungals
15 Mwesigwa Douglas
Challenges Faced By Medicines And Therapeutic Committees In Regional Referral And District General Hospitals In Eastern And North Eastern Uganda
16 Marie-Laure Laroche
Economic burden of hospital admission due to an adverse drug reaction in France: the IATROSTAT ECO study
17 Maxine Gossell-Williams
Promoting Curricular Inclusion of Pharmacovigilance Awareness Among Medical Students Through A Research Skill Training Module
18 Flory Tsobo Muanda
Fluoroquinolone and Risk of Nightmares: A Disproportionality Analysis
21 Joana Félix
Pharmacovigilance Assessors’ Experiences Interacting with Narrative Fields in Spontaneous Reports: an Exploratory Interview Study
22 Teodoro Oscanoa
Association Between the NAT2 Gene and Pyrazinamide-induced Liver Injury in Peruvian Patients with Tuberculosis
24 Haona Li
Medication-related falls in older adults: a Bibliometric Review of Global Research
26 Xi Jin (Susie) Wang
Changing the course of the opioid epidemic one risk communication at a time
28 Teodoro Oscanoa
Effect of the CYP4F2 Gene on Warfarin Dose in Anticoagulated Peruvian Patients
29 Clément Jambon-Barbara
Signal detection of drugs associated with obstructive and central sleep apnoea
30 Gwenaelle Veyrac
Drug induced enterocolitis syndrome : a new clinical entity
31 Gwenaelle Veyrac
Erythema scarlatiniforme desquamativum recidivans with amoxicillin: study of the French pharmacovigilance database
32 ChenYang Bai
Masking Bias in Active Comparator Designs for Data Mining in Pharmacovigilance
33 Teodoro Oscanoa
Association Between Drug Transporter Gene SLCO1B1 With Pyrazinamide-induced liver Injury in Peruvian Patients with tuberculosis
34 Marie-Laure Laroche
Cannabinoids and adverse convulsive events: An analysis of the French pharmacovigilance and addictovigilance databases
36 Margarida Sousa
Adverse Events Related to Etonogestrel Implant: An Old But Still Current Issue?
37 Guillermo Keller
Safety In Pregnancy Of Equine Antivenom In The Treatment Of Accidents With Poisonous Animals
38 Guillermo Keller
Preliminary Report Of Multicenter Study On Safety Evaluation Of Off-label Use Of Cannabis Products For Anxiety, Insomnia And Chronic Pain
39 Joana Félix
Drug-induced Liver Injury Assessment in VigiBase
41 Payam Peymani
Leveraging Machine Learning and Artificial Intelligence in a Novel Multi-Agent Intelligent System for Pharmacovigilance: Early-Stage Development Study
43 Aleksandra Schwarzrock-Fabian
Dosing instructions on prescription to improve medication safety – a cross sectional study on German community pharmacists
44 Bouraoui Ouni
Celecoxib-induced leucocytoclastic vasculitis: A case report
45 Bouraoui Ouni
Atorvastatine induced acute pancreatitis: case report
46 Bouraoui Ouni
Anaphylactic shock induced by infliximab with positive skin test: A case report
47 Bouraoui Ouni
Rifampicin induced Drug rash with eosinophilia and systemic symptoms (DRESS) with positive rechallenge
48 Jean-Luc Faillie
Fluoroquinolones Use and Risk of Hospitalization for Spontaneous Pneumothorax: A Nationwide Case-Time-Control Study
49 Jean-Luc Faillie
Can We Ask ChatGPT About Drug Safety? Appropriateness of ChatGPT Responses to Questions about Drug Use and Adverse Reactions
50 Bouraoui Ouni
Vancomycine infusion induced anaphylactic shock: a case report
52 Bouraoui Ouni
Assessment of Residents of Medicine Level of Knowledge in Pharmacovigilance (Faculty of Medicine of Sousse, Tunisia)
53 Jean-Luc Faillie
Serious Acute Pancreatitic Reaction in the Context of Misuse of Dulaglutide for Weigh Loss: A Case Report
54 Bouraoui Ouni
Causes of under-reporting of adverse events and Solution according to Residents of Medicine (Faculty of Medicine of Sousse, Tunisia)
55 Jean-Luc Faillie
Allergy-Like Nocebo Events with COVID-19 Vaccination are Associated With Age, History Of allergy, Vaccine Type and Poor Perception of Effectiveness
56 Ela Bogoridov
Unlocking Safety Insights: Integrating Pharmacovigilance and Patient Support Program Data
57 Laura Costantino
Suspected Adverse Reactions Of Eptinezumab In The Treatment Of Headache: Real-World Data From EudraVigilance Database.
58 Victoria Munoz Goyette
Influence of External Factors on Spontaneous Reporting Practices: An Analysis of FAERS Data
59 Laura Costantino
Analysis Of ADRs Detected During a Retrospective Study In a Geriatric Department
60 Laura Costantino
Analysis Of The Risk Of Gastrointestinal Bleeding In The Elderly Patient And Evaluation Of The Impact Of Antithrombotics.
61 Maria Storey
Responding to reports of colchicine fatalities in New Zealand
62 Laura Costantino
Analysis Of The Risk Of QT Prolongation In The Elderly Patients Undergoing Polypharmacy.
63 bouraoui Ouni
Adverse Drug Reactions (ADRs) associated with Anti-Tuberculosis drugs: retrospective study
64 Bouraoui Ouni
Anti-tuberculosis drugs (ATDs) induced hepatotoxicity
65 Bouraoui Ouni
Priapism induced by Sertraline: case report
66 Francois Montastruc
Psychiatric decompensation after discontinuation of antiemetic neuroleptics
67 Pallavi Pradhan
Canadian Clinical Context: A Replicability and Validation study of Naranjo Causality Assessment Tool
68 Ikra Ashraf
An audit on adherence to Medicines and Healthcare products Regulatory Agency guidance to reduce risk in Rheumatoid Arthritis patients on Janus Kinase Inhibitors.
70 Sonia Corbin
Overview of causality assessment of adverse events among drug users in a tertiary hospital setting: a retrospective study
71 Daniel Malek
Paternal exposure to medicines leading to detrimental outcomes in offspring: A scoping review
72 Sofia Attelind
GENOME-WIDE ASSOCIATION STUDY OF DIRECT ORAL ANTICOAGULANTS AND THEIR RELATION TO BLEEDING
73 Atefeh Jafari
Sacubitril-valsartan and Risk of Alzheimer-type dementia: A Disproportionality Analysis
74 Karen Schmidt
A Patient Safety Competency Model for Measuring and Building Pharmacovigilance Skills in a Developing Organization
75 Avani Shah
A Proprietary Solution for Resource Management in Safety Organizations, Centered around Individual and Organization Skillsets
76 Payam Peymani
Enhancing Safety: A Proof-of-Concept Pilot Study to Establish a Framework for Pan-Canadian 2SLGBTQI+ Medication Safety Initiatives
79 Aileen Chua
Perspectives and Challenges of Marketing Authorisation Holders in Implementing a Pregnancy Prevention Programme (PPP) in Singapore
80 Raffaella Di Napoli
Looking to the future: Disproportionality analysis provides critical insights into CAR T-cell safety and secondary malignancy risk (FAERS Pharmacovigilance Database)
81 Pedro Miguel
Neurological and Neuropsychiatric Adverse Drug Reactions to Integrase Strand Transfer Inhibitors: 10-Year Review of Reports to the European Pharmacovigilance System
82 Steven Black
Training Programs to Develop a Pool of DSMB members from LMICs and Training for LMIC Vaccine Clinical Trial Investigators
84 Sieara Plebon-Huff
Annual Report of Adverse Reactions Associated with Cannabis Products Reported to Health Canada, 2022
85 Yingjia Chen
Enhancing Patient Safety with Dashboard for Advanced Safety Analytics Exploration: A Step Towards Proactive, Personalized, and Predictive Drug Safety Management
86 Yingjia Chen
Risk factor identification for anemia and immune-related hepatitis in NSCLC Patients Treated with PDL1/PD1: single-source vs meta-analysis coefficient estimates
87 Yingjia Chen
Enhancing pharmacovigilance through methods-driven comparability of cross-data source analyses of anemia and immune-mediated hepatitis in NSCLC patients treated with PD-1/PD-L1 therapies
88 Shweta Todkar
Comprehensive analysis of heart failure management: Insights from Vision C+ registry
89 Gladys Martha Delgado Perez
Virtual interconsultations to a clinical pharmacy service to reduce underreporting of adverse drug reactions
90 Francois Montastruc
Concomitant use of antipsychotics and progestogens: an increased risk of reporting galactorrhea?
92 Ella van Vliet
Knowing me, knowing you – Lessons learned from three European studies on European Medicines Agency’s risk communication
93 Florencia Amato
Follow-Up of Pure Red Cell Aplasia Associated to Hemax®, a Biosimilar Epoetin Alfa.
95 Florencia Amato
Vitreous Detachment and Teriparatide (Osteofortil): Case Report and Literature Review.
96 Marine Auffret
Adverse events reported with medical cannabis during the French experimentation
97 Julien Mahé
Cutaneous Adverse Events Associated With Enfortumab Vedotin: A Critical Analysis of French Pharmacovigilance Data
98 Brahim Azzouz
Venlafaxine and Reversible Cerebral Vasoconstriction Syndrome: Data from VigiBase® and Literature.
99 Florencia Amato
Skin Ulcers at Injection Sites Under Interferon-Beta 1a in a Multiple Sclerosis Patient: Case Report.
100 Brahim Azzouz
Skin Papilloma after Upadacitinib Exposure: Data from VigiBase®.
101 Floraise Lynda Tanguenan
Are Serious Adverse Events Reported in the Quebec Population Treated for Heart Failure?
102 Jorge Emanuel Da Silva Monteiro
Evaluation of Oncology Medicinal Products Risk Minimisation Measures: a Review of Studies Registered in the European Medicines Agency (HMA-EMA) Catalogue
103 Nassir Mirfendereski
Opioid Analgesic-Associated Adrenal Insufficiency : A Dual-Approach Pharmacovigilance Study
104 Elizabeth Teketel
Implementing an Active Surveillance Study of Patients Treated with a Tenofovir/Lamivudine/Dolutegravir (TLD) Regimen for HIV in Mozambique
106 Sylvine Pinel
Ocrelizumab (Ocrevus(r)) induced neutropenia: study in the French Pharmacovigilance Database
107 Brahim Azzouz
Depression Risk with Teriparatide: Disproportionality Analysis and Potential Mechanisms.
108 Elizabeth Teketel
Institutionalizing a Digital System for Active Tuberculosis Drug Safety Monitoring in the Philippines
109 Clarice Ambale
Improving awareness on pharmacovigilance reporting in Kenya
110 Elizabeth Teketel
Strengthening the Adverse Events Following Immunization Surveillance System for COVID-19 Vaccine Safety Monitoring and beyond: a case of Tanzania
111 Guillermo Keller
An Approach to the Risk-Benefit Evaluation of Antivenoms Based on Bothrops Bites Cases from Digital Records
112 Cecilia Beltran
level of knowledge about pharmacovigilance in undergraduate students of medicine and pharmacy in Lima-Peru
113 Christian Kapinga
Impact of stringent vigilance systems for medical devices and Invitro diagnostics in Africa: A case study in Tanzania
115 Rebecca Preyra
Sulfamethoxazole-trimethoprim and Risk of Blood Disorders: An Active Comparator Restricted Disproportionality Analysis
116 Rebecca Preyra
Safety of Sulfamethoxazole-trimethoprim for the Treatment of Bacterial Infection in Outpatient Settings: A Meta-analysis and Pharmacovigilance Study
117 Fatemeh Soleymani
Monitoring the Effects of the COVID-19 Pandemic on Antidepressant Utilization Trends in Iran
119 Gloria Shalviri
Medication Errors Reporting by Nurses Through Electronic Reporting System, a Realist Review.
120 Juanina da Costa
The Current Pharmacovigilance System in Timor-Leste by an Indicator-Based Assessment Tool
121 Juanina da Costa
The Characteristics of Individual Case Safety Reports (ICSRs) in Timor-Leste
122 Ghadeer Banasser
Technological Tools and Guidelines in Medication Name Screening: SFDA’s Approach and Outcomes
123 Aseel Alshayji
Improving Medication Safety in Saudi Healthcare System: The Role of Regional Pharmacovigilance Officers (RPVOs) in Implementing Additional Risk Minimization Measures
124 Ahmed Hassan
Adverse events associated with sodium-glucose co-transporter-2 inhibitors: A UK National Pharmacovigilance Study
125 Caroline Joyau
Carpal tunnel syndrome and immune checkpoint inhibitors: review of french pharmacovigilance database and literature
126 Priscilla Lopes
A Feasibility Assessment Of The FDA Adverse Event Reporting System For The Detection Of Cannabis-Related Safety Signals
128 Sarah Banholzer
Hepatic Disorders Associated with GLP-1 Receptor Agonists: Analysis of individual case safety reports in VigiBase
130 Amal Arafah
Classification and Evaluation of Pre-Authorized Pharmacovigilance Agreements of Advanced Therapy Medicinal Products Related Marketing Authorization Holders (MAHs): An Observational Study
131 Mehdi Benkebil
A Risk Minimization Tool For Drug Exposure During Pregnancy: A Multidisciplinary Approach To Reassess The Pregnancy Pictogram On Medication Packaging
132 Mulatedzi Makhado
Integration Of Electronic TB Register (EDRWeB) And Pharmacovigilance Monitoring System (PViMS) To Improve Clinica Governance
133 Abdullatif Alotaibi
Comprehensive Analysis of Pharmacovigilance Inspections Findings: Focus on inspection Topics in the Pharmaceutical Industry in Saudi Arabia
134 Niaz Chalabianloo
Comparative Safety Analysis of Serious Adverse Drug Events in North America: A 19-Year Study of FDA and Canadian Vigilance Databases
135 Laurent Chouchana
Use of methylphenidate and reporting of valvular heart disease: global pharmacovigilance analysis in children and adults
137 Laurent Chouchana
Safety of ifosfamide during pregnancy: a comprehensive analysis
138 Brian Savwa
Magnitude and Predictors of Drug Therapy Problems Among Patients with Leukemia at a National Referral Hospital in Kenya.
140 Fatemeh Ahmadi
Trimethoprim/sulfamethoxazole and Risk of Acute Respiratory Failure in Youth and Adolescents: A Disproportionality Analysis
141 Mayra Martho
The Implementation of KPI (Key Performance Indicators) to Manage the Pharmacovigilance System of a Public Vaccine Producer in Brazil
142 Mohammed Salem
Pre-Existing Comorbidities as Risk Factors for Myocarditis/Pericarditis Following mRNA COVID-19 Vaccination in Young Males: An Observed Versus Expected Analysis
143 Masayoshi Nakakuni
Safety Signal Detection of Hepatocellular Injury following Methotrexate Administration in Children with Cancer and Rare Diseases
146 Fátima Roque
A codesign approach for designing qualitative study for exploring knowledge and attitudes related to the use of antibiotics in animals
148 Vitor Roque
Enhancing Public Awareness of Antibiotic Resistance Through Regulatory Agencies’ Social Media Users Engagement in Portugal
149 Fátia Roque
Guideline for Antimicrobial Prescription in Food-producing Animals in OECD-related countries: a contribution for OneHealth
150 Ana Margarida Advinha
Rivaroxaban Risk Management: Qualitative Analysis of Portuguese Educational Materials
153 Mohammed Fouda
Evaluating Machine Learning Models for Predicting Saudi Pharmacovigilance Risk Management Measures
154 Alhanouf Aldajani
Spontaneous reporting of adverse reactions related to Antiplatelet Drugs in Saudi Arabia
155 João Fernandes
Antipsychotic Abuse and Dependence: a 10-year Review of Reports to the European Pharmacovigilance System
156 Anne Lise Ruellan
Pharmacovigilance of innovative long-acting injectable antiretroviral therapy: a post-marketing retrospective study
157 João Fernandes
Melatonin Safety Profile in the Neuropsychiatric Pediatric Setting − a Retrospective Global Study
158 Shazia Hasan
Targeted Pharmacovigilance for Metronidazole-Induced Neuropathy in Patients of Amoebic Liver Abscess at A Tertiary Care Hospital: An Ambispective Study
159 Laurent Chouchana
Pregnancy outcomes in females living with cystic fibrosis exposed to CFTR modulators: early findings from a French nationwide cohort study
160 Marie Liles-Burden
Viability of Serious Gaming in Effective Risk Minimization
161 Fotoun Alblowi
The Top Reported Medications Associated with Life-Threatening Adverse Drug Events in Saudi Arabia: Insights from a Spontaneous Reporting System
162 Laurent Chouchana
Association between neurodevelopmental disorders reporting in offspring and antidepressant use during pregnancy
164 Maude Lavallée
Impact of mandatory report on adverse event declaration in an academic tertiary center of Quebec
165 Laurent Chouchana
Prenatal exposure to proton pump inhibitors and risk of serious infections in offspring: a nationwide cohort study
166 Yassine Aimer
Pharmacy Survey in the City of Saida: Pharmaceutical Waste Management
168 Sandra Mendoza
Partnerships and Pharmacovigilance Agreements Regulations in Latin America
169 Fatemeh Ahmadi
Automating Population-Based Studies for 30-Day Adverse Drug Event Detection in Older Adults with Chronic Kidney Disease Using High-Throughput Computing
171 Dalil Boulefaa
Sudden Sensorineural Hearing Loss After mRNA COVID-19 Vaccination: Early Safety Signal Generation Using Disproportionality Analysis on a Nationwide Pharmacovigilance Database
173 Bobet Aurélie
INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS AND CARDIOVASCULAR ADVERSE DRUG REACTIONS: RESULTS OF THE FRENCH PHARMACOVIGILANCE SURVEY
174 Delphine Bourneau-Martin
Frozen shoulder after COVID-19 vaccination : A review of covid-19 vaccines surveillance in France
175 Khadija Lechheb
ARTIFICIAL INTELLIGENCE: REVOLUTIONIZING PHARMACOVIGILANCE FOR ENHANCED DRUG SAFETY
176 Fatima Ait El Hadj
Acute hepatitis and phytovigilance : A case report
178 Hager Saleh
ISoP Medication errors SIG: Integrated Antimicrobial Resistance Action (IARA) Program
179 Veselinka Vukicevic
Are Men and Women Equal When it comes to Valproates – Analysis of Prescribing practice in Montenegro
180 Marco Bonaso
Questionnaire-Based Survey Investigating ADR Spontaneous Reporting Knowledge, Experiences and Attitudes in Italian Oncology Wards
182 Marie Briet
Cyclin-Kinase 4/6 Inhibitors and Renal Failure: a Study Based on the French National Pharmacovigilance Database
183 Raffaella Di Napoli
Major Adverse Cardiovascular Events related to JAK inhibitors: a disproportionality analysis using WHO global individual case safety database.
184 Szandra Marton
Impact of Additional Risk Minimization Measures on Prescribing Patterns: An Interrupted Time Series Analysis
185 Inês Tavares
Effectiveness of Educational Materials as Additional Risk Minimization Measures for Faricimab (Vabysmo®), Aflibercept (Eylea®) and Ranibizumab (Lucentis®) – The MARVEL Study
186 Anders Sundström
Pulmonary Embolism and COVID-19 Vaccinations in 2021 and 2022: a Study in a Swedish Population of 7.5 Million People
187 Nino Solagadze
Awareness of Adverse Drug Reaction Reporting Among the Physicians in Georgia
188 Ryan Walker
Knowledge Communities: What Are They, How Do They Work, and Why Are They Key to Strengthening the Global Pharmacovigilance Ecosystem?
189 Veronique Kugener
The American Program in Pharmacovigilance (Am2P): A new accredited training program in Pharmacovigilance and Pharmacoepidemiology
190 Garo Safaian
Applications of Artificial Intelligence and Machine Learning in Pharmacovigilance and Drug Safety
191 Candice Drinkwater
A Systematic Literature Review of the Long-term Adverse Events Associated with COVID-19 Vaccines
192 Jose Alberto Ayala Ortiz
Education in Pharmacovigilance, creation of the Pharmacovigilance Classroom in collaboration with the University of Granada.
193 Jefferson Santiago Piedra Andrade
Increase in antibiotic resistance in a specialty hospital between two periods from january 2018 to december 2023: a cross-sectional study.
194 Jean-Christophe Delumeau
Update on the initiatives developed by the ISoP SiG on Risk Minimisation Methods
195 Aleksandra Milosavljevic
Exploring Stakeholders’ Experiences and Views on Capturing Traditional, Complementary, and Alternative Medicine Exposures in Routinely Collected Health Data
197 Roberto Da Cas
Sex differences in reporting suspected adverse drug reactions in Italy
199 Jukai Huang
Multiple evidences for safety evaluation of Chinese Patent Medicines
200 Elizabeth Teketel
Strengthening Pharmacovigilance and Safety Surveillance in Bangladesh
201 Cristina Morciano
A Self-Controlled Case Series Study To Evaluate Neurological Events After Influenza Vaccination In Italy: TheShinISS-Vax Flu Post-Marketing Surveillance
202 Francesco Salvo
Use of artificial Intelligence-based assistant tool: quantitative and qualitative feedback from pharmacovigilance professionals of French Network of Pharmacovigilance Centers.
203 Magnus Ekelo
Enhancing Detection and Reporting of Medication Errors Through Online Learning.
Can an Online Course Bring About Any Actual Change?
204 Valeria Belleudi
Pharmacological Therapy in Patients with Gender Dysphoria: A Cohort Study in the Lazio Region, Italy
205 Giuseppe Cicala
Dual Orexin Receptor Antagonists versus Z-drugs: a Disproportionality Analysis Using WHO Drug Safety Database
206 Cecilia Cagnotta
Sex differences in beta-blocker-related adverse events: a pharmacovigilance comparative analysis of metoprolol and carvedilol in heart failure using EudraVigilance data
207 Michelle Hines
Intoxicating Novel Cannabinoid Products Involved in Adverse Event Reports Received by the Food and Drug Administration
208 Aurore Morel
Association between Anti-PD-1/PD-L1 Drugs and Hearing Impairment
209 Leah Herity
Safety Signal Identification for Risankizumab-rzaa in the Sentinel Distributed Database Using Self-Controlled and Active Comparator Study Designs
210 Paola Maria Cutroneo
Post-Marketing Surveillance of polatuzumab vedotin: a disproportionality analysis of the US FDA Adverse Event Reporting System (FAERS) database
211 Andreia Rodrigues Lopes, MD, PharmD
Selective Serotonin Reuptake Inhibitors and Venous Thromboembolism: a Pharmacovigilance Analysis of the Eudravigilance Database
212 Abdallah Alami
Safety of RSV Vaccine among Pregnant Individuals: A Real-World Pharmacovigilance Study Using Vaccine Adverse Event Reporting System
213 Eileen Farnon
Preparing for Vaccine Adverse Event of Special Interest-X (AESI-X): a standardized approach applied to novel vaccines
214 Tchadji Mayoudom Vanessa Edwige
Targeted detection of pharmaceutical residues in fish and macroinvertebrates around the waste water treatment at Yaounde University Teaching Hospital , Cameroon
216 Elena Berti
Analysis Of ADR In Oncology Patients Treated With Fluoropyrimidines With Known And Unknown Genotype In Relation To DPYD Gene Polymorphisms
217 Ugo Moretti
Comparison of different NLP systems to extract adverse drug reaction information from the medicinal product information
218 Elizabeth Teketel
Strengthening Pharmacovigilance in Rwanda, Introducing PViMS for Spontaneous Reporting of Adverse Drug Effects
219 Claire Bernardeau
Are causal claims reported in disproportionality analysis using individual case safety reports exacerbated in related citations? A meta-research study
220 Andy Stergachis
Landscape Assessment of Active Safety Surveillance of Novel Vaccines in Low- and Middle-Income Countries
222 Hager Saleh
Exploring Drug Knowledge Base Usage in Medical Education: Perspectives and Practices Among Medical Students
224 Seun Onasanya
A Systematic Review of Pharmacovigilance System in Africa: Performance, Challenges, and Option to Enhance Pharmacovigilance.
226 Ilma Bertulyte
Genome-Wide Association Study on Possible Association Between Inflammatory Neuropathies and SARS-CoV2 Vaccines
227 Marie Jones
A Systematic Review of Case Reports of Allergic and Hypersensitivity ADRs Associated with PEG-Granulocyte Colony-Stimulating Factor (PEG-GCSF) and PEG-Asparaginase (PEG-ASE).
230 João Fernandes
Unraveling Psychotic Disorders: A 10-Year Analysis of Cases Received by the Portuguese National Pharmacovigilance System
231 João Fernandes
Defective Medicines: A Retrospective Review of Cases Received by the Portuguese National Pharmacovigilance System Over the Last Ten Years
233 Ana Silva
Adverse Drug Reactions Reported by Community Pharmacists in the Last 6 Years – A Landscape Analysis
236 Ana Silva
ADR Reports in Portugal: Healthcare Professionals vs Consumers – 10 Years of Experience
237 Atheer Aldayel
Visits to Healthcare Units to Raise Awareness and Improve Implementation of Additional Risk Minimization Measures (aRMMs) in Saudi Healthcare Settings
238 Afaf Bouqoufi
The Crucial Role of Teratovigilance in Assessing Medication Risks During Pregnancy
239 Najd Alabdulrahman
Risk Communication about Medications: Initiatives for Improvement in Saudi Arabia
240 Afaf Bouqoufi
Teratogenic effect of medicinal plants used during pregnancy by pregnant women from EMRO‘s region: A Systematic Review
241 Afaf Bouqoufi
DRUG SAFETY DURING PREGNANCY: THE BIG CHALLENGE OF MATERNAL AND NEONATAL HEALTH
245 Agnès Lillo
Pharmacovigilance and Onco-Cardiology: a synergistic interaction.
246 Jeremiah Ewudzie-Sampson
The Use of Mobile Application Versus Other Reporting Channels for Adverse Events Reporting During COVID-19 Vaccine Deployment in Ghana
247 Adela Ashie
A Decade of Implementation Good Pharmacovigilance Practice in Lower Middle-Income Country: A Case Study from Ghana
249 Daniela Daza
A Guide for the Correct Management of High-Risk Drugs as a Tool for Integrated Key Stakeholders in Colombia
250 Adela Ashie
A Deep Dive into the National Pharmacovigilance Data: Analysis of Adverse Drug Reactions Reported to Contraceptive Use
252 Abena Asamoa-Amoakohene
Haemovigilance in a Low- and Middle-Income Country; Ghana’s Experience
253 Adela Ashie
Development of Vaccine Related Event (VRE) Response Plan: A Case Study of Ghana
254 Ronald Kiguba
Impact of the Med Safety App on Adverse Drug Reaction Reporting by Health Workers in Uganda: A Cluster-Randomized Controlled Trial
257 Marina Malikova
Safety and risk-management in clinical trials with tissue regenerative products.
258 Marina Malikova
Impact of social determinants of health on safety of patients in device clinical trials conducted at a safety-net hospital.
259 Sun-Young Jung
Factors associated with Immune-related Adverse Events in Immune Checkpoint Inhibitor Users
260 Yesenia Rodríguez
Assessment of adverse events due to BBIBP-CorV vaccine in a Peruvian Pharmacovigilance Center
262 Cinthya Galicia
Development and Implementation of a Health Transformational Leadership workshop to Health Care Professionals in México.
263 Liliana Vargas Neri
Pharmacovigilance activities for the early detection of Drug-related problems (DRPs) on antibiotic therapy in hospitalized pediatric patients an integral part of an Antimicrobial Stewardship Program (ASP).
264 Evelyne Pierron
Enhanced surveillance of adverse reactions to COVID-19 vaccines in France: Feedback with Three examples of Signals
265 Obaidur Reza Choudhury
ADVANCING PATIENT SAFETY THROUGH PHARMACOVIGILANCE IN BANGLADESH’S GROWING PHARMACEUTICAL SECTOR
266 Johanna Meyer
What Influences Major Influencers of COVID-19 Vaccination Decisions? Evidence from South Africa
267 Preeti Khard
Signal Detection and Management for Vaccines
269 Nouzha Lazli
Assessment of Severe Adverse Effects of a dietary supplement containing Resveratrol and Quercetin dihydrate
271 Alex Dodoo
Standardizing QPPV Training in Africa: Development and Implementation of a Comprehensive Curriculum and Objective Assessments for Enhanced Pharmacovigilance Competency
272 나영 손
Evaluating The Risk of Cardiac Arrhythmia in Patients Taking Sodium Channel Blockers Using Real World Data in Korea
